Cybin has announced positive Phase 2 topline safety and efficacy data for its proprietary deuterated psilocybin analogue – CYB003 – for the treatment of major depressive...
Compass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched.
Psychedelic therapy company Sunstone Therapies has announced the start of its first study investigating multiple doses of psilocybin in the treatment of major depression disorder (MDD)...
Beckley Psytech has confirmed it has dosed the first patient in its international Phase 2b study of BPL-003 – a novel synthetic intranasal formulation of 5-MeO-DMT...
Multiple studies have shown that ketamine is a fast acting treatment for depression, but a key issue with the studies is that many participants can tell...
Results from a major clinical trial have shown that esketamine outperforms one of the standard treatments for treatment-resistant major depression disorder (MDD).
Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major...
Cybin Inc.
Marking a world first, researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin as a treatment for gambling addiction with the support of funding from...
The final cohort of patients has been dosed in Cybin’s Dosing Phase 2 Trial investigating CYB003 – an investigational deuterated analogue of psilocybin – as a...
